GlassScriptPhysician profile
Tara Ann Dullye
NPI 1437146230
$9,189.56
in general payments reported to CMS, 2019-2025
34 companies · $5,211 in 2025
The $5,211 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $218 · 2021: $267 · 2022: $311 · 2023: $391 · 2024: $2,650 · 2025: $5,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,400 · Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,400.00 |
| Food and Beverage | $851.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $7,400.00 | 2024-2025 | Bovine Collagen |
| Millicent US INC | $206.80 | 2020-2025 | Intrarosa, Femlyv |
| Astellas Pharma US INC | $191.84 | 2023-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $173.18 | 2019-2022 | |
| Pfizer INC. | $102.48 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $80.11 | 2022-2023 | |
| Abbvie INC. | $76.31 | 2019-2022 | |
| Avion Pharmaceuticals | $74.41 | 2019-2022 | |
| Shield Therapeutics INC | $65.76 | 2022-2025 | Accrufer |
| Lilly USA, LLC | $60.54 | 2023-2025 | Zepbound |
| Lsi Solutions INC | $55.33 | 2022 | |
| Aspira Women'S Health INC | $54.05 | 2022-2023 | Ova1 |
| Amag Pharmaceuticals, INC. | $53.78 | 2019-2020 | |
| Exact Sciences Corporation | $50.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $49.26 | 2023-2024 | Wegovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $45.68 | 2023-2025 | Biofix, Biodfactor, Biodoptix |
| Caldera Medical, INC | $43.26 | 2021 | |
| Exeltis, USA INC. | $40.96 | 2021-2023 | Slynd |
| Coopersurgical, INC. | $38.02 | 2020-2024 | Fisherbrand Disposable Liquid Infant Heel Warmer |
| Agile Therapeutics, INC. | $36.20 | 2021-2022 | |
| Sage Therapeutics, LLC | $32.17 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $31.70 | 2023 | NP Thyroid 60 |
| Lupin INC. | $29.42 | 2020-2021 | |
| Zyla Life Sciences, INC. | $28.11 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $22.57 | 2025 | Exparel |
| Allergan, INC. | $22.41 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $18.49 | 2023 | Caldolor |
| Bayer Healthcare Pharmaceuticals INC. | $18.47 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.64 | 2023 | Adthyza |
| Biohaven Pharmaceutical Holding Company LTD. | $16.33 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.51 | 2023 | Quviviq |
| Minerva Surgical, INC | $14.70 | 2022 | |
| Evofem Biosciences, INC. | $12.33 | 2021 | |
| Mylan Pharmaceuticals INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Dullye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.